Tuesday Scientific Session: Deep Vein and Pelvic Disorders

Deep Venous Valve and DVT Outcomes

A two-year follow-up of a bioprosthetic venous valve trial found strong clinical
improvement despite the device not receiving FDA approval, with thrombotic complications
concentrated in patients with complex bifid venous anatomy. A propensity-matched analysis
found no difference in post-thrombotic syndrome rates between mechanical thrombectomy and
anticoagulation for isolated femoral popliteal DVT at one or two years, though thrombectomy
patients felt better sooner.

Stent Classification and Patency

A proposed classification tied to femoral vein inflow strongly predicted iliofemoral
stent patency, with heavily involved inflow linked to high rethrombosis rates. A separate
talk argued that stent success should be defined by symptom relief and absence of
complications, not patency alone, since some widely patent stents fail to resolve
symptoms.

Pelvic Disorders and Emerging Science

Long-term data showed sustained pain relief up to 36 months after endovenous treatment
for pelvic venous disorders, with combined ovarian vein and iliac stenting providing faster
relief. Basic science presentations explored stent endothelialization timelines and mTOR
inhibition to reduce post-thrombotic vein wall fibrosis.